NovaBridge Biosciences (NBP) Operating Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly Operating Margin of 789260.0% for Q4 2023, down 23279.43% quarter-over-quarter from 3375.87% in Q3 2023.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Operating Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Operating Margin for 2 consecutive years, with 789260.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, Operating Margin changed N/A year-over-year to 789260.0%; the TTM figure through Dec 2023 stood at 4469691.91% (changed N/A YoY), while the FY2023 annual figure was 11395.09%, down 797292.0% from the prior year.
- Operating Margin fell to 789260.0% in Q4 2023 per NBP's latest filing, from 3375.87% in the prior quarter.
- Across five years, Operating Margin topped out at 2042.94% in Q3 2019 and bottomed at 789260.0% in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -789,260.00% |
| Sep 30, 2023 | -3,375.87% |
| Jun 30, 2023 | -7,578.62% |
| Dec 31, 2020 | 76.00% |
| Sep 30, 2019 | -2,042.94% |